Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

Thrombosis and haemostasis - 1 Jan 2004

Gage Brian F, Eby Charles, Milligan Paul E, Banet Gerald A, Duncan Jill R, McLeod Howard L

Abstract excerpt

Knowledge of pharmacogenetics may help clinicians predict their patients' therapeutic dose of warfarin, thereby decreasing the risk of bleeding during warfarin initiation. Our goal was to use pharmacogenetics to develop an algorithm that uses genetic, clinical, and demographic factors to estimate the warfarin dose a priori. We collected a blood sample, demographic variables, laboratory values, smoking status,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation

Share to Cytochrome P-450 CYP2C9

Share to International Normalized Ratio

Share to Pharmacogenetics

Share to Regression Analysis

Share to Warfarin

Source

Identifiers

PMID: 14691573
DOI: 10.1160/TH03-06-0379

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.PMID 14691573Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

Pharmacogenetics in warfarin therapySemantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Estimation of the warfarin dose with clinical and pharmacogenetic data.Semantic proximity Read ↗

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.Semantic proximity Read ↗

Influence of polymorphisms in CYP2C9, VKORC1, MDR1 and APOE genes on the warfarin maintenance dose in Brazilian patients.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.Semantic proximity Read ↗

Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.Semantic proximity Read ↗

Warfarin pharmacogenetics: does more accurate dosing benefit patients?Semantic proximity Read ↗

Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort.Semantic proximity Read ↗

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.